HirtzRLibudaLHinneyAFckerMBhlmeierJAntelJet alLack of evidence for a relationship between the hypothalamus-pituitary-adrenal and the hypothalamus-pituitary-thyroid axis in adolescent depression
NDC Package Code : 10695-331 Start Marketing Date : 2026-01-20 End Marketing Date : 2027-12-31 Dosage Form (Strength) : POWDER (1kg/kg) Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others GDUFA DMF Review : N/A Rev
If no, go to step iii
FIGURE 6 5.1 In vitro tests Caudatin has been found to exhibit significant growth inhibition and induces apoptosis in a variety of cancer cell lines, such as hepatocellular carcinoma cell lines (HepG2 and SMMC-7721), breast carcinoma cell line (MCF-7) and lung carcinoma cell line (A549), with IC 50 values ranging from 3.11 to 44.68 mol/L ( 5.2 In vivo tests Studies conducted in animals such as rats and mice showed that caudatin did not cause significant side effects or systemic toxicity at therapeutic doses ( 6 Conclusion This review highlights the therapeutic viability of caudatin from structural optimization, pharmacological mechanism, and clinical implications, suggesting it as a multi-facilitive scaffold for drug discovery
